Efficacy and Safety of switching to Pasireotide in Acromegaly Patients controlled with Pegvisomant and Somatostatin Analogues: PAPE extension study.

Ammar Muhammad,Eva C Coopmans,Patric J D Delhanty,Alof H G Dallenga,Iain K Haitsma,Joseph A M J L Janssen,Aart J van der Lely,Sebastian J C M M Neggers,Patrick Delhanty,A J Van der Lely
DOI: https://doi.org/10.1530/EJE-18-0353
2019-10-03
European Journal of Endocrinology
Abstract:to assess the efficacy and safety after 48 weeks of treatment with pasireotide long-acting-release (PAS-LAR) alone or in combination with pegvisomant in patients with acromegaly. In addition, we assessed the relation between insulin secretion and pasireotide-induced hyperglycemia.
endocrinology & metabolism
What problem does this paper attempt to address?